Associated Papers
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Comparison of the transport kinetics of fexofenadine and its pH dependency among OATP1A2 genetic variants.
Han H et al.
Drug Metabolism and Pharmacokinetics, 2022
Comparison of the inhibitory properties of the fruit component naringenin and its glycosides against OATP1A2 genetic variants.
Araki N et al.
Drug Metabolism and Pharmacokinetics, 2022
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Genetic variability and population diversity of the human SLCO (OATP) transporter family.
Zhang B et al.
Pharmacological Research, 2019
The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries.
Costa ACC et al.
European Journal of Clinical Pharmacology, 2017
Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance.
Lee HH et al.
Molecular Pharmacology, 2017
Genetic polymorphisms and function of the organic anion-transporting polypeptide 1A2 and its clinical relevance in drug disposition.
Zhou Y et al.
Pharmacology, 2015
Functional analysis of novel polymorphisms in the human SLCO1A2 gene that encodes the transporter OATP1A2.
Zhou F et al.
The Aaps Journal, 2013
Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.
Clarke JD et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Environmental and genetic factors affecting transport of imatinib by OATP1A2.
Eechoute K et al.
Clinical Pharmacology and Therapeutics, 2011
Pharmacogenetics of the organic anion transporting polypeptide 1A2.
Franke RM et al.
Pharmacogenomics, 2009
Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants.
Badagnani I et al.
The Journal of Pharmacology and Experimental Therapeutics, 2006
Implications of genetic polymorphisms in drug transporters for pharmacotherapy.
Kerb R
Cancer Letters, 2006
Pharmacogenomics of human OATP transporters.
König J et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2006
Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry.
Lee W et al.
The Journal of Biological Chemistry, 2005